Royal Philips, University of Colorado and BioIntellisense received a $2.8 million grant from the Department of Defense to validate the remote patient monitoring startup's wearable device's ability to early detect COVID-19.
The U.S. Army Medical Research and Development Command selected Philips, Aurora-based University of Colorado and BioIntellisense for the clinical study, which will comprise 2,500 eligible participants who have a recently known COVID-19 exposure and/or are experiencing early symptoms, according to the Dec. 22 news release.
University of Colorado's medical school will help test BioIntellisense's wearable device, which monitors the user's heart rate, respiratory rate and temperature. With the collaboration, the organizations aim to advance the use of wearable diagnostics to help with early identification and containing presymptomatic COVID-19 cases.